Intellia Therapeutics Names Bill Chase to its Board of Directors
17 Avril 2023 - 10:01PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage
genome editing company focused on developing potentially curative
therapies leveraging CRISPR-based technologies, today announced the
appointment of Bill Chase, MBA, to its board of directors. Mr.
Chase will be a member of the audit committee and will succeed
Caroline Dorsa as chair of the audit committee upon her retirement
from the board. Ms. Dorsa is retiring from Intellia’s board,
effective June 15, 2023, as a result of her appointment as chair of
Biogen’s board of directors.
“Bill’s extensive track record as an experienced financial and
business leader makes him a valuable addition to our board, as we
continue to shape the future of genomic medicines and advance our
first investigational CRISPR-based therapies into late-stage
clinical development,” said Intellia President and Chief Executive
Officer John Leonard, M.D. “All of us at Intellia thank Caroline
for her dedicated service and many contributions to Intellia’s
growth and success and wish her much success in her future
endeavors.”
Mr. Chase has over three decades of strategic and financial
management experience at leading life science companies. He
previously served as executive vice president and chief financial
officer of AbbVie, following the company’s successful spinout from
Abbott Laboratories, in 2012 until 2018. He then went on to serve
as executive vice president, Finance and Administration from
October 2018 to July 2019.
Prior to his tenure at AbbVie, Mr. Chase spent almost 25 years
in financial management positions of increasing seniority at
Abbott, including corporate vice president, Licensing &
Acquisitions; corporate vice president and treasurer; and
divisional vice president and controller of Abbott International.
He also serves on the board of Parexel International, one of the
industry’s largest clinical research organizations. Mr. Chase holds
a bachelor’s degree in finance from the University of Illinois and
a Master of Business Administration from the University of Chicago
Booth School of Business. About Intellia
Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing
company, is developing novel, potentially curative therapeutics
using CRISPR/Cas9 technology. To fully realize the transformative
potential of CRISPR/Cas9, Intellia is pursuing two primary
approaches. The company’s in vivo programs use
intravenously administered CRISPR as the therapy, in which
proprietary delivery technology enables highly precise editing of
disease-causing genes directly within specific target tissues.
Intellia’s ex vivo programs use CRISPR to create the
therapy by using engineered human cells to treat cancer and
autoimmune diseases. Intellia’s deep scientific, technical and
clinical development experience, along with its robust intellectual
property portfolio, have enabled the company to take a leadership
role in harnessing the full potential of CRISPR/Cas9 to create new
classes of genetic medicine. Learn more at intelliatx.com.
Follow us on Twitter @intelliatx.
Forward-Looking Statements
This press release contains “forward-looking statements”
of Intellia Therapeutics, Inc. (“Intellia”, “we” or “our”)
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include, but are not
limited to, express or implied statements regarding Intellia’s
beliefs and expectations regarding the safety, efficacy and
advancement of our clinical programs and the anticipated
contribution of the members of our board of directors, specifically
Bill Chase, and our executives to our operations and progress.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: the risk
that any one or more of our product candidates, including those
that are co-developed, will not be successfully developed and
commercialized, including risks related to the authorization,
initiation and conduct of studies and other development
requirements for our product candidates such as advancing
CRISPR-based therapies into late-stage clinical development; the
risk that the results of preclinical studies or clinical studies
will not be predictive of future results in connection with future
studies; risks related to our relationship with third parties,
including our licensors, licensees and other collaborators; and
risks related to our, and our licensors’, ability to protect and
maintain our intellectual property position. For a discussion of
these and other risks and uncertainties, and other important
factors, any of which could cause Intellia’s actual results to
differ from those contained in the forward-looking statements, see
the section entitled “Risk Factors” in Intellia’s most recent
annual report on Form 10-K, as well as discussions of potential
risks, uncertainties, and other important factors in Intellia’s
other filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and Intellia undertakes no duty to update this information unless
required by law.
Intellia Contacts:
Investors:Ian KarpSenior Vice President,
Investor Relations and Corporate
Communications+1-857-449-4175ian.karp@intelliatx.com
Lina LiSenior Director, Investor Relations and Corporate
Communications+1-857-706-1612lina.li@intelliatx.com
Media:Rebecca SpaldingTen Bridge
Communications+1-646-509-3831media@intelliatx.comrebecca@tenbridgecommunications.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024